|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We investigated whether a predefined combination of the Arg389Gly polymorphism in the adrenergic β(1) -receptor gene (ADRB1) and the Gln27Glu polymorphism in the adrenergic β(2) -receptor gene (ADRB2) could predict survival in carvedilol- and metoprolol-treated chronic heart failure (HF) patients.
|
21395649 |
2011 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The present study sought to investigate whether ADRB1 Arg389Gly (rs1801253), GNAS -1211 G/A (rs6123837) and GNAS 2291 C/T (rs6026584) variants are associated with left ventricular function and exercise tolerance in heart failure patients.
|
23065660 |
2013 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We tested the hypothesis that polymorphisms at codons 389 (Arg389Gly) and 49 (Ser49Gly) of the beta(1)-adrenergic receptor would be associated with differences in initial tolerability of beta-blocker therapy in patients with heart failure.
|
15735607 |
2005 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated antiarrhythmic effects and increased efficacy for preventing heart failure events in patients homozygous for the major allele of the ADRB1 Arg389Gly polymorphism (ADRB1 Arg389Arg genotype).
|
29754666 |
2018 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Arg389Gly polymorphism has a major impact on the heart-rate response to carvedilol (but not bisoprolol) in patients with heart failure plus atrial fibrillation.
|
22617224 |
2012 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single nucleotide polymorphisms (SNPs) within the β(1)- (Ser49Gly, Arg389Gly) and β(2)-adrenoceptor (Arg16Gly, Gln27Glu, Thr164Ile) have been associated with alterations in adrenoceptor (AR) function sensitivity in vitro and in vivo and possibly contribute to HF progression.
|
20803192 |
2010 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We used uniform methodology to investigate BB dose-ADRB1 Arg389Gly polymorphism interaction with major clinical end points in BEST/bucindolol and HF-ACTION/other BB databases.
|
30354340 |
2018 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We examined whether the Arg389Gly polymorphism in ADRβ1 interacts with the dose requirements of beta-blockers in patients with systolic HF.
|
23115322 |
2013 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The objective of this study was to determine whether ADRB1 Ser49Gly and Arg389Gly are associated with recovery of left ventricular ejection fraction (LVEF) in patients with heart failure.
|
30756358 |
2019 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the β1 adrenergic receptor gene Arg389Gly polymorphism might not be associated with heart failure risk.
|
26125791 |
2015 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One study of risk for heart failure suggested a synergistic effect of ADRB1 Arg389Gly with the insertion/deletion polymorphism in the alpha2C-adrenergic receptor gene (ADRA2C).
|
17496726 |
2007 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study.
|
12921807 |
2003 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since the pivotal role of β1 adrenergic receptor (β1-AR) in HF, many publications have studied the associations between the β1-AR polymorphisms (Ser49Gly and Arg389Gly) and HF, with inconsistent results.
|
22815685 |
2012 |
|
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The β1 adrenergic receptor (ADRB1) Arg389Gly, G-protein receptor kinase type 5 (GRK5) Gln41Leu, G-protein β-3 subunit (GNB3) 825 C/T, and α2c deletion affect adrenergic tone, impact heart failure outcomes and differ in prevalence by ethnicity.
|
30978507 |
2019 |
|
rs76992529
|
|
|
0.070 |
GeneticVariation |
BEFREE |
After the age of 65 years (CHS), the frequencies of congestive heart failure (38% vs 15%, relative risk 2.62, P = .04) and mortality (76% vs 53%, relative risk 1.46, P = .08) were higher in V122I allele carriers than in age-, gender- and ethnically matched controls.
|
20435197 |
2010 |
|
rs76992529
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This clinical algorithm may be useful for identification of ATTR V122I amyloidosis in elderly African American patients with HF.
|
28196196 |
2017 |
|
rs76992529
|
|
|
0.070 |
GeneticVariation |
BEFREE |
It appears to be far less common than the previously described Val122Ile mutation but onset may be at an earlier age, potentially making heart transplantation a viable option should heart failure become severe.
|
23126592 |
2012 |
|
rs76992529
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We did not detect a significant difference in mortality between V122I TTR allele carriers and noncarriers, a finding that contrasts with prior observations; however, the risk of heart failure was increased among carriers.
|
25551524 |
2015 |
|
rs76992529
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks, the TTR V122I genetic variant was significantly associated with heart failure.
|
31821430 |
2019 |
|
rs76992529
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Transthyretin amyloidosis associated with variant V122I (ATTR V122I) is likely to be an important cause of heart failure in Afro-Caribbean populations, but the high prevalence of left ventricular hypertrophy (LVH) and lack of awareness of this genetic disorder pose diagnostic hurdles.
|
22795285 |
2012 |
|
rs76992529
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Patients with ATTR V122I had the worst prognosis compared with other causes of Afro-Caribbean heart failure and white patients.
|
27618855 |
2016 |
|
rs1799983
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Homozygosity for the G allele of the eNOS G894T polymorphism was associated with worse survival in systolic HF patients, especially in those treated with nitrates.
|
25917853 |
2015 |
|
rs1799983
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Endothelial nitric oxide synthase (eNOS) Glu298Asp single nucleotide polymorphism (SNP) genotype has been associated with a worse phenotype amongst patients with established heart failure and in patients with progression of their renal disease.
|
25612295 |
2015 |
|
rs1799983
|
|
|
0.060 |
GeneticVariation |
BEFREE |
This prospective study was designed to analyze the impact of three eNOS polymorphisms (T-786C, VNTR4a/b and Glu298Asp) and their haplotypes on the susceptibility and clinical outcomes in HF outpatients with systolic dysfunction.
|
22290017 |
2012 |
|
rs1799983
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Endothelial nitric oxide synthase Glu298Asp gene polymorphism in a multi-ethnical population with heart failure and controls.
|
20079452 |
2010 |